You are here: Industry Insights > JW Therapeutics

News List

The Second CAR-T Therapy in China Applied for Marketing PharmaSources/Dopine
July 01, 2020
On June 30, according to the official website of CDE, the marketing application of a CAR-T therapy, JWCAR029 by JW Therapeutics was accepted by CDE.
JW Therapeutics Announces Two Appointments to Strengthen R&D Capability and Pipeline Building prnasia
January 10, 2022
JW Therapeutics (HKEx: 2126), an independent, innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products...
JW Therapeutics Presents Primary Clinical Response on Carteyva(R) (relmacabtagene autoleucel injection) in Adults with Relapsed/Refractory Follicular Lymphoma in China at the 63rd ASH Annual Meeting prnasia
December 15, 2021
JW Therapeutics (HKEx: 2126), an independent innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products...
JW Therapeutics Announces IND Approval for the Clinical Trial of JWCAR129 prnasia
September 28, 2021
JW Therapeutics (HKEx: 2126), an innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, today announced that it has received the Investigational New Drug...
JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in China prnasia
September 13, 2021
SHANGHAI, Sept. 6, 2021 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products
Thermo Fisher, JW Therapeutics Form CAR-T Partnership in China contractpharma
February 09, 2021
Thermo Fisher Scientific has signed an agreement with cell therapy company JW Therapeutics to ensure non-exclusive commercial access to Thermo Fisher's Gibco CTS Dynabeads CD3/CD28.
Leading Cell Therapy Company JW Therapeutics Lists on Main Board of HKEX prnasia
November 04, 2020
JW Therapeutics today celebrates the initial public offering (IPO) on the Main Board of the Stock Exchange of Hong Kong, S.A.R., China Limited.
JW Therapeutics Acquires Syracuse Biopharma and Its in-Licenses With Eureka Therapeutics' Solid Tumor Technologies in China prnasia
July 20, 2020
JW Therapeutics, a clinical stage biopharmaceutical company focused on developing, manufacturing and commercializing cell therapies for patients in China, today announced the acquisition of Syracuse Biopharma (Hong Kong, S.A.R., China) Limited, which incl